Eric Dube

Eric Dube, Ph.D., is the president and chief executive officer of Travere Therapeutics and serves as a member of the company’s board of directors. He is a results-driven leader who is committed to patients and integrating their perspectives into all aspects of the company’s operations. At Travere Therapeutics, Dr. Dube oversees a global team dedicated to identifying, developing, and delivering life-changing therapies to people living with rare diseases, as well as the advancement of the company’s promising pipeline featuring an innovative product candidate with first-in-class potential. With leadership experience across the United States, Europe, and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical and business development functions.

Prior to joining Travere Therapeutics, Dr. Dube was president and head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy, and investment decisions for the company’s North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain, and alliance management. During Dr. Dube’s tenure at GSK, he also led the US Oncology and Global Respiratory businesses. He currently serves on the board of trustees for AIDS United, the executive committee of the board of directors for the Biotechnology Innovation Organization (BIO), and the board of directors for Biocom California and Reneo Pharmaceuticals.